Improvement bioavailability of silymarin ameliorates severe dyslipidemia associated with metabolic syndrome
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
- Klíčová slova
- ABC transporters, CYP4A, CYP7A1, HDL-cholesterol,
- MeSH
- ABC transportéry metabolismus MeSH
- biologická dostupnost MeSH
- cholesterol-7-alfa-hydroxylasa metabolismus MeSH
- cytochrom P450 CYP4A metabolismus MeSH
- dyslipidemie krev komplikace farmakoterapie MeSH
- játra účinky léků enzymologie MeSH
- lipidy krev MeSH
- metabolický syndrom krev komplikace farmakoterapie MeSH
- potkani Wistar MeSH
- silymarin farmakologie terapeutické užití MeSH
- western blotting MeSH
- zvířata MeSH
- Check Tag
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- ABC transportéry MeSH
- cholesterol-7-alfa-hydroxylasa MeSH
- CYP7A1 protein, rat MeSH Prohlížeč
- cytochrom P450 CYP4A MeSH
- lipidy MeSH
- silymarin MeSH
1. To compare the effectiveness of different drug forms of silymarin: standardized extract of silymarin (SS), micronized silymarin (MS) and silymarin in the form of phytosome (PS) on dyslipidemia and liver fat accumulation in a model of metabolic syndrome, in non-obese hereditary hypertriglyceridemic rats. The second aim of this study was to slightly uncover the silymarin action on enzymes and proteins involved in cholesterol metabolism and excretion. 2. Silymarin administered to hereditary hypertriglyceridemic rats as dietary supplements (1%) for 4 weeks significantly lowered the plasma levels of triglycerides, total cholesterol and markedly increased HDL cholesterol level. Western blot analyses showed significant increase in the protein expression of CYP7A1 and CYP4A and increase in protein expression of selected ABC transporters. Silymarin in the form of phytosome and micronized silymarin were more effective forms of silymarin. 3. These findings suggest that silymarin may favorably affect the metabolism of cholesterol and triglycerides in rats with metabolic syndrome. Raising HDL levels suggests potentially important anti-atherogenic effect of silymarin. The changes in expression of cytochromes P450 and ABC transporters involved in cholesterol metabolism and excretion could be partially responsible for the hypolipidemic effect of silymarin.
Citace poskytuje Crossref.org
